

- Alfaris N., Waldrop S., Johnson V., Boaventura B., Kendrick K., and Stanford F., 2024, GLP-1 single dual and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review, *eClinicalMedicine*, 75: 102782.
<https://doi.org/10.1016/j.eclinm.2024.102782>
- Anderson J., 2020, Combining glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors to target multiple organ defects in type 2 diabetes, *Diabetes Spectrum*, 33: 165-174.
<https://doi.org/10.2337/ds19-0031>
- Aronne L., Hall K., Jakicic J., Leibel R., Lowe M., Rosenbaum M., and Klein S., 2021, Describing the weight-reduced state: physiology behavior and interventions, *Obesity*, 29: S9-24.
<https://doi.org/10.1002/oby.23086>
- Bednarz K., Kowalczyk K., Cwynar M., Czapla D., Czarkowski W., Kmita D., Nowak A., and Madej P., 2022, The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome, *International Journal of Molecular Sciences*, 23(8): 4334.
<https://doi.org/10.3390/ijms23084334>
- Berg S., Stickle H., Rose S., and Nemec E., 2025, Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: a systematic review and meta-analysis, *Obesity Reviews*, 26: e13929.
<https://doi.org/10.1111/obr.13929>
- Budini B., Luo S., Tam M., Stead I., Lee A., Akrami A., Vidal-Puig A., and Park A., 2025, Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression, *medRxiv*, 9: 2025-06.
<https://doi.org/10.1101/2025.06.09.25328726>
- Fadel L., Thao G., Chitre T., Rojas E., Fricko M., Domingo V., Budginas B., Guerrero L., Ghatas M., Arani N., Tabatabai N., and Pemminati S., 2025, A system-based review on effects of glucagon-like peptide-1 receptor agonists: benefits vs risks, *Cureus*, 17(2): e78575.
<https://doi.org/10.7759/cureus.78575>
- Gourdy P., Darmon P., Diévert F., Halimi J., and Guerci B., 2023, Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM), *Cardiovascular Diabetology*, 22(1): 79.
<https://doi.org/10.1186/s12933-023-01798-4>
- Hamed K., Alosaimi M., Ali B., Alghamdi A., Alkhashi T., Alkhaldi S., Altowarqi N., Alzahrani H., Alshehri A., Alkhaldi R., Alqahtani K., Alharbi N., Alhulayfi H., Sharifi S., and Dighriri I., 2024, Glucagon-like peptide-1 (GLP-1) receptor agonists: exploring their impact on diabetes obesity and cardiovascular health through a comprehensive literature review, *Cureus*, 16(9): e68390.
<https://doi.org/10.7759/cureus.68390>
- Ilias I., Zabulienė L., and Rizzo M., 2025, GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks, *Frontiers in Clinical Diabetes and Healthcare*, 5: 1530811.
<https://doi.org/10.3389/fcdhc.2024.1530811>
- Iqbal J., Wu H., Hu N., Zhou Y., Li L., Xiao F., Wang T., Jiang H., Xu S., Huang B., and Zhou H., 2022, Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials, *Obesity Reviews*, 23(6): e13435.
<https://doi.org/10.1111/obr.13435>
- Jensen S., Blond M., Sandsdal R., Olsen L., Juhl C., Lundgren J., Janus C., Stallknecht B., Holst J., Madsbad S., and Torekov S., 2024, Healthy weight loss maintenance with exercise GLP-1 receptor agonist or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial, *eClinicalMedicine*, 69: 102475.
<https://doi.org/10.1016/j.eclinm.2024.102475>
- Kheniser K., Saxon D., and Kashyap S., 2021, Long-term weight loss strategies for obesity, *The Journal of Clinical Endocrinology and Metabolism*, 106(7): 1854-1866.
<https://doi.org/10.1210/clinem/dgab091>
- Kojta I., Chacińska M., and Blachnio-Zabielska A., 2020, Obesity bioactive lipids and adipose tissue inflammation in insulin resistance, *Nutrients*, 12(5): 1305.
<https://doi.org/10.3390/nu12051305>
- Liu X., and Shu M., 2025, Application and mechanism of GLP-1 receptor agonists in the treatment of obesity complicated with type 2 diabetes mellitus, *International Journal of Public Health and Medical Research*, 3(3): 69-74.
<https://doi.org/10.62051/ijphmr.v3n3.08>
- Liu Y., Ruan B., Jiang H., Le S., Liu Y., Ao X., Huang Y., Shi X., Xue R., Fu X., and Wang S., 2023, The weight-loss effect of GLP-1RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials, *The American Journal of Clinical Nutrition*, 118(3): 614-626.
<https://doi.org/10.1016/j.ajcnut.2023.04.017>
- Madsbad S., and Holst J., 2025, The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines, *Expert Opinion on Investigational Drugs*, 34: 197-215.
<https://doi.org/10.1080/13543784.2025.2472408>
- Maple-Brown L., Shaw J., Hare M., Ng E., and Wood A., 2022, Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes, *Australian Journal of General Practice*, 51(7): 513-518.
<https://doi.org/10.31128/ajgp-07-21-6057>